局部区域复发早期结外鼻型NK/T细胞淋巴瘤挽救治疗初步预后分析

doi:10.3760/cma.j.issn.1004-4221.2017.01.010

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (792 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract

Objective To retrospectively analyze the prognostic factors for locoregionally recurrent early-stage extranodal nasal-type natural killer/T-cell lymphoma (NKTCL). Methods A total of 56 patients with early-stage extranodal nasal-type NKTCL, who had locoregional recurrence after initial treatment and then received salvage treatment from 1995 to 2014, were enrolled as subjects. The effects of salvage treatment on the overall survival (OS) rate were analyzed after initial treatment and recurrence. Univariate and multivariate prognostic analyses were performed on the OS rate after recurrence. Results The median follow-up time was 35.9 months after initial treatment and 14.8 months after recurrence. The 3-year OS rate was 73% after initial treatment and 58% after recurrence. Compared with chemotherapy alone, radiotherapy-containing salvage treatment significantly improved the OS rates after initial treatment and recurrence (P=0.040, 0.009), and re-irradiation also significantly improved the OS rates after initial treatment and recurrence (P=0.018, 0.019). Most (84%) of the acute and late adverse reactions after re-irradiation were grade 1-2 ones. The univariate and multivariate analyses showed that the Karnofsky Performance Status score, radiotherapy in initial treatment, and radiotherapy in salvage treatment were influencing factors for the OS rate after recurrence. Conclusions Radiotherapy achieves improved survival and tolerable toxicities, making it indispensable in the treatment of locoregionally recurrent extranodal nasal-type NKTCL.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Tong Qin
	Luo Yanrong
	Zhang Yujing
	Feng Lingling
	Li Yiyang
	Wang Hanyu
	Xia Yunfei
	Ai Xiaohong

Key words： Extranodal NK/T cell lymphoma Lymphoma/radiotherapy Recurrence Factor analysis

Received: 06 May 2016

Corresponding Authors: Zhang Yujing,Email:zhangyj@sysucc.org.cn

Cite this article:

Tong Qin,Luo Yanrong,Zhang Yujing et al. Salvage treatment outcome and prognosis of patients with locoregionally recurrent early-stage extranodal NK/T cell lymphoma,nasal type[J]. Chinese Journal of Radiation Oncology, 2017, 26(1): 45-49.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2017.01.010 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2017/V26/I1/45

[1] Fang H,Jin J,Wang WH,et al. Prognostic factors and treatment outcomes for patients with stage Ⅱ extranodal nasal-type natural killer/T-cell lymphoma of the upper aerodigestive tract[J].Leuk Lymphoma,2014,55(8):1832-1837.DOI:10.3109/10428194.2013.852668.
[2] Zhang J,Zhu MY,Wang L,et al.“Sandwich” chemotherapy (CT) with radiotherapy (RT) improves outcomes in patients with stage ⅠE/Ⅱ_E extranodal natural killer (NK)/T-cell Lymphomas[J].Asian Pac J Cancer Prey,2013,14(7):4061-4066.DOI:10.7314/APJCP.2013.14.7.4061.
[3] Avilés A,Neri N,Fernández R,et al. Combined therapy in untreated patients improves outcome in nasal NK/T lymphoma:results of a clinical trial[J].Med Oncol,2013,30(3):637.DOI:10.1007/s12032-013-0637-1.
[4] Li YX,Liu QF,Wang WH,et al. Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy[J].Cancer,2011,117(22):5203-5211.DOI:10.1002/cncr.26167.
[5] Kim K,Chic EK,Kim CW,et al. Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma,nasal type:radiotherapy versus chemoradiotherapy[J].Jpn J Clin Oncol,2005,35(1):1-5.DOI:10.1093/jjco/hyi006.
[6] 杨勇,张玉晶,林旭滨,等.放疗在早期鼻型NK/T细胞淋巴瘤综合治疗中作用及预后分析[J].中华放射肿瘤学杂志,2009,18(4):285-289.DOI:10.3760/cma.j.issn.1004-4221.2009.04.285.
Yang Y,Zhang YJ,Lin X,et al. Role of radiotherapy in the combined treatment of patients with early stage extranodal nasal type NK/T-cell lymphoma and analysis of prognostic factors[J].Chin J Radiat Oncol,2009,18(4):285-289.DOI:10.3760/cma.j.issn.1004-4221.2009.04.285.
[7] 牛邵清,张玉晶,温戈,等.早期原发鼻腔NK/T细胞淋巴瘤局部扩大野IMRT前瞻性Ⅱ期研究的初步结果[J].中华放射肿瘤学杂志,2015,24(4):377-381.DOI:10.3760/j.issn.1004-4221.2015.04.006.
Niu SQ,Zhang YJ,Wen G,et al. Preliminary results of a phase Ⅱ prospective clinical study of early-stage nasal NK/T-cell lymphoma with extended involved-field intensity-modulated radiotherapy[J].Chin J Radiat Oncol,2015,24(4):377-381.DOI:10.3760/j.issn.1004-4221.2015.04.006.
[8] Cheson BD,Horning SJ,Coiffier B,et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas[J].J Clin Oncol,1999,17(4):1244-1253.
[9] Zhao T,Li YX,Wang SL,et al. Survival benefit with salvage radiotherapy for patients with locoregionally recurrent extranodal NK/T cell lymphoma,nasal type[J].Ann Hematol,2013,92(3):325-332.DOI:10.1007/s00277-012-1611-2.
[10] Li CC,Tien HF,Tang JL,et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma[J].Cancer,2004,100(2):366-375.DOI:10.1002/cncr.11908.
[11] Koom WS,Chung EJ,Yang WI,et al. Angiocentric T-cell and NK/T-cell lymphomas:radiotherapeutic viewpoints[J].Int J Radiat Oncol Biol Phys,2004,59(4):1127-1137.DOI:10.1016/j.ijrobp.2003.12.006.
[12] Zhang XX,Xie CH,Xu Y,et al. Salvage treatment improved survival of patients with relapsed extranodal natural killer/T-cell lymphoma,nasal type[J].Int J Radiat Oncol Biol Phys,2009,74(3):747-752.DOI:10.1016/j.ijrobp.2008.08.066.
[13] 陈波,李晔雄,刘清峰,等.早期结外鼻型NK/T细胞淋巴瘤疗后远期复发因素分析[J].中华放射肿瘤学杂志,2013,22(3):175-179.DOI:10.3760/cma.j.issn.1004-4221.2013.03.001.
Chen B,Li YX,Liu QF,et al. Analysis of risk factors for late relapse in early-stage extranodal nasal-type NK/T-cell lymphoma after treatment[J].Chin J Radiat Oncol,2013,22(3):175-179.DOI:10.3760/cma.j.issn.1004-4221.2013.03.001.
[14] Ma HH,Qian LT,Pan HF,et al. Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma[J].Med Oncol,2010,27(3):798-806.DOI:10.1007/s12032-009-9288-7.
[15] Lee J,Cho SG,Chung SM,et al. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL),nasal type,stage Ⅰ—Ⅱ_E:single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL)[J].Ann Hematol,2013,92(3):333-343.DOI:10.1007/s00277-012-1630-z.
[16] Yamaguchi M,Tobinai K,Oguchi M,et al. Phase Ⅰ/Ⅱ study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma:Japan clinical oncology group study JCOG0211[J].J Clin Oncol,2009,27(33):5594-5600.DOI:10.1200/JCO.2009.23.8295.
[17] Wang H,Li YX,Wang WH,et al. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma[J].Int J Radiat Oncol Biol Phys,2012,82(3):1115-1121.DOI:10.1016/j.ijrobp.2011.02.039.
[18] Kim SJ,Park Y,Kim BS,et al. Extranodal natural killer/T-cell lymphoma with long-term survival and repeated relapses:does it indicate the presence of indolent subtype?[J].Korean J Hematol,2012,47(3):202-206.DOI:10.5045/kjh.2012.47.3.202.
[19] Jaccard A,Gachard N,Marin B,et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma,a phase 2 study[J].Blood,2011,117(6):1834-1839.DOI:10.1182/blood-2010-09-307454.
[20] Yamaguchi M,Kwong YL,Kim WS,et al. Phase Ⅱ study of SMILE chemotherapy for newly diagnosed stage ⅠV,relapsed,or refractory extranodal natural killer (NK)/T-cell lymphoma,nasal type:the NK-Cell Tumor Study Group study[J].J Clin Oncol,2011,29(33):4410-4416.DOI:10.1200/JCO.2011.35.6287.